Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Patent
1995-10-16
1998-05-05
Hutzell, Paula K.
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
435 72, 435 721, 514 2, 530350, G01N 3353
Patent
active
057472629
ABSTRACT:
Compositions for identifying lead compounds for pharmacological agents useful in the diagnosis or treatment of neurological disease or injury include mixtures comprising an isolated netrin and an isolated natural netrin receptor such as "Deleted in Colorectal Carcinoma" (DCC) and neogenin. The general methods involve incubating a mixture of an isolated mammalian netrin, an isolated natural mammalian netrin receptor, and a candidate pharmacological agent, and determining if the presence of the agent modulates the binding of the netrin to the receptor.
REFERENCES:
patent: 5565331 (1996-10-01), Tessier-Lavigne et al.
Cho et al, Current Opinion in Genetics and Development: 5 (1995) pp. 72-78.
Colamarino et al. Cell:81 (1995) 621-629.
Jackowski et al. British Journal of Neurosurgery: 9 (1995) pp. 303-317.
Hinck Lindsay
Lavigne Marc Tessier
Leonardo David
Masu Kasuko
Masu Masayuki
Bakalyar Heather A.
Hutzell Paula K.
Osman Richard Aron
The Regents of the University of California
LandOfFree
Neurological drug screens does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Neurological drug screens, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Neurological drug screens will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-52697